Adrenocortical carcinoma - Improving patient care by establishing new structures

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 2, 2006, Pages 45-51

  Koschker, A C ^a   Fassnacht, M ^a   Hahner, S ^a   Weismann, D ^a   Allolio, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

ACC; Adrenocortical carcinoma; ENSAT; FIRM ACT; Registry

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLUTETHIMIDE; KETOCONAZOLE; MITOTANE; STEROID HORMONE;

ABDOMINAL ABSCESS; ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RARE DISEASE; REVIEW; SURGICAL TECHNIQUE;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MUTATION; TREATMENT OUTCOME;

EID: 33645454783     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-923808     Document Type: Review

References (24)

1. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol 2004; 60: 273-287
2. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicine and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma. A large prospective phase II trial. Endocrine Related Cancer 2005; 12: 657-666
3. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001; 25: 914-926
4. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Edited. Lyon: IARC Press, 2004: 136
5. Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy? J Endocrinol Invest 2004; 27: 387-399
6. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003; 162: 521-531
7. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005; 6: 386-394
8. Kann PH, Wirkus B, Behr T, Klose KJ, Meyer S. Endosonographic imaging of benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2004; 89: 1694-1697
9. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson B. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000; 11: 1281-1287
10. Lee AS, Galea C, DiGiammarino EL, Jun B, Murti G, Ribeiro RC, Zambetti G, Schultz CP, Kriwacki RW. Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant. J Mol Biol 2003; 327: 699-709
11. Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF, Burgess MA, Evans DB. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995; 118: 1090-1098
12. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195-1201
13. MacFarlane DA. Cancer of the adrenal cortiex: the natural history, prognosis and treatment in the study of fifty cases. Ann R Coll Surg Engl 1958; 109: 613-618
14. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238
15. National-Cancer-Institute. Third national cancer survey: incidence data. In: DHEW Publ. No. (NIH) 75-787. NCI monograph, edited., pp.41, Bethesda: National Cancer Institute, 1975
16. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001; 98: 9330-9335
17. Saeger W, Fassnacht M, Chita R, Prager G, Nies C, Lorenz K, Barlehner E, Simon D, Niederle B, Beuschlein F, Allolio B, Reincke M. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. Hum Pathol 2003; 34: 180-186
18. Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa-ha K, Hirata Y, Mizoguchi H, Sugimura T, Terada M, Yokota J. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst 1992; 84: 703-707
19. Schteingart DE, Doherty PG, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP. Management of patients with adrenal cancer - recommendations of an international consensus conference. 2005; 12: 667-680 (Review)
20. Sredni ST, Zerbini MC, Latorre MR, Alves VA. p53 as a prognostic factor in adrenocortical tumors of adults and children. Braz J Med Biol Res 2003; 36: 23-27
21. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978; 120: 660-665
22. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994; 86: 1707-1710
23. Wajchenberg B, Albergaria PM, Medonca B, Latronico A, Campos CP, Ferreira AV, Zerbini M, Liberman B, Carlos GG, Kirschner M. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88: 711-736
24. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-3155